Claims for Patent: 9,662,377

Summary for Patent: 9,662,377

Title:	Therapeutic composition for treatment of glioblastoma
Abstract:	The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).
Inventor(s):	Olin; Michael Raymond (Minneapolis, MN), Ohlfest; John R. (Minneapolis, MN), Low; Walter (Minneapolis, MN)
Assignee:	REGENTS OF THE UNIVERSITY OF MINNEOSTA (Minneapolis, MN)
Application Number:	15/135,292
Patent Claims:	1. A method of eliciting an immune response in an animal in need thereof, comprising administering to the animal an anti-tumor composition comprising an adherent glioblastoma GBM6-AD stem cell, wherein the adherent glioblastoma GBM6-AD stem cell is ATCC.RTM. Patent Deposit Designation PTA-11498. 2. The method of claim 1, further comprising administering Imiquimod to the animal. 3. The method of claim 2, wherein the Imiquimod is administered topically, intradermally, subcutaneously, and/or via intralymph node injections. 4. The method of claim 1, wherein the anti-tumor composition is administered parenterally, orally or intranasally. 5. The method of claim 1, wherein the anti-tumor composition is administered at more than one time point. 6. The method of claim 1, wherein the anti-tumor composition is administered at a dose of 100,000-100 million GBM6-AD cells at each administration time point. 7. The method of claim 1, further comprising administering irradiation therapy to the animal. 8. The method of claim 7, wherein the irradiation therapy is administered at a dose of less than 6,000 cGY. 9. The method of claim 7, further comprising administering a radiation sensitizer to the animal. 10. The method of claim 9, wherein the radiation sensitizer is a parp inhibitor or temozolomide. 11. The method of claim 1, wherein the animal is a mammal. 12. The method of claim 1, further comprising administering dexamethasone therapy to the animal. 13. The method of claim 12, wherein the dexamethasone therapy is administered at the time of diagnosis. 14. The method of claim 1, further comprising administering a chemotherapy or drug that depletes regulatory T cell or myeloid derived suppressor cells. 15. The method of claim 14, wherein the chemotherapy is sunititib, ontak, cyclophosphamide, gemcitabine, and/or retionoic acid.

Details for Patent 9,662,377

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eisai, Incorporated	ONTAK	denileukin diftitox	Injection	103767	02/05/1999		2030-10-25